论文部分内容阅读
目的探讨纤维连接蛋白对多发性骨髓瘤化疗敏感性及其临床价值。方法采用MTT法测量柔红霉素、羟基喜树碱、金喜素和康莱特注射液对骨髓瘤细胞的细胞毒性 ;流式细胞仪定量检测凋亡细胞并计算细胞凋亡倍数。结果纤维连接蛋白能使骨髓瘤耐受化疗药物的细胞毒作用 ,柔红霉素、羟基喜树碱、金喜素和康莱特注射液的耐药倍数分别为 8.3、9.7、5 .2和 4 .4 ;并能抑制化疗药物诱导的细胞早期凋亡 ,上述化疗药物的细胞凋亡倍数分别为 0 .31、0 .6 0、0 .5 7和 0 .33。结论纤维连接蛋白能降低多发性骨髓瘤对化疗药物的敏感性 ,通过抑制化疗药物诱导的细胞凋亡 ,参与骨髓瘤早期耐药的形成 ,从而为临床逆转多发性骨髓瘤耐药提供新的思路。
Objective To investigate the sensitivity of fibronectin to chemotherapy in multiple myeloma and its clinical value. Methods MTT method was used to measure the cytotoxicity of daunorubicin, hydroxycamptothecin, quetiapine and Kanglaite injection on myeloma cells; apoptosis was quantified by flow cytometry and the apoptosis ratio was calculated. Results Fibronectin could make myeloma resistant to the cytotoxic effect of chemotherapy drugs. The multiple of drug resistance of daunorubicin, hydroxycamptothecin, azithromycin and Kanglaite injection were 8.3, 9.7, 5.2 and 4 respectively .4; And can inhibit the chemotherapy-induced cell apoptosis in the early stage, the apoptosis rate of the chemotherapy drugs were 0.31,0. Conclusions Fibronectin can reduce the sensitivity of multiple myeloma to chemotherapeutic drugs. It can participate in the formation of early drug resistance of myeloma by inhibiting the apoptosis induced by chemotherapeutic drugs and provide new ideas for reversing the drug resistance of multiple myeloma. .